Clarivate Plc has released a new report, "Radioligand Innovators Ushering in a New Era of Precision Oncology," highlighting emerging companies in the field of radioligand therapies (RLTs)—innovative treatments that merge nuclear medicine with biotechnology for targeted cancer therapy. The report details the significant advancements and strategic growth in RLTs, which aim to improve cancer treatment by delivering radiation directly to tumor cells while minimizing harm to healthy tissue. Key developments include major acquisitions and the projected market growth of the global radiopharmaceutical sector, which is expected to exceed $13 billion in the next decade. The report emphasizes the importance of collaborations, innovative R&D strategies, and the need to overcome regulatory challenges.
Mon, 16 Jun 2025 08:00:00 GMT | Financial Times